** Shares of therapy developer Marinus Pharmaceuticals
fall ~61.5% to 65 cents premarket
** Co says it is discontinuing development of its oral drug ganaxolone after it missed the main goal in a late-stage trial in patients with a rare genetic brain disease called tuberous sclerosis complex (TSC)
** MRNS says the drug did not show a significant reduction in frequency of TSC-associated seizures
** Co says it is exploring strategic alternatives and is taking additional steps to reduce costs, including a reduction in its workforce
** Up to last close, stock down 84.5% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。